Marc Grenley

1.9k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Marc Grenley is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Marc Grenley has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Marc Grenley's work include Cancer Immunotherapy and Biomarkers (3 papers), interferon and immune responses (2 papers) and Cancer Research and Treatments (2 papers). Marc Grenley is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), interferon and immune responses (2 papers) and Cancer Research and Treatments (2 papers). Marc Grenley collaborates with scholars based in United States, Japan and Germany. Marc Grenley's co-authors include Bruce A. Edgar, Huaqi Jiang, Alexander Kohlmaier, Donald G. McEwen, Parthive H. Patel, Rachel Z. Blumhagen, Richard A. Klinghoffer, Sally Ditzler, Joyoti Dey and Edward F. Kleinman and has published in prestigious journals such as Cell, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Marc Grenley

10 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the Drosophila Midgut

2009 776 citations Huaqi Jiang, Parthive H. Patel et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Grenley United States	5	813	533	468	357	138	11	1.2k
Paul Badenhorst United Kingdom	18	299 0.4×	1.5k 2.9×	222 0.5×	138 0.4×	97 0.7×	23	1.9k
Renjie Jiao China	18	165 0.2×	1.1k 2.0×	177 0.4×	153 0.4×	64 0.5×	39	1.3k
Rita Sinka Hungary	18	216 0.3×	995 1.9×	176 0.4×	146 0.4×	68 0.5×	42	1.6k
Jeanette E. Natzle United States	17	177 0.2×	603 1.1×	440 0.9×	189 0.5×	20 0.1×	20	1.1k
François Bonnay Austria	10	249 0.3×	366 0.7×	80 0.2×	190 0.5×	43 0.3×	11	698
Thomas Twardzik Germany	8	283 0.3×	412 0.8×	148 0.3×	24 0.1×	82 0.6×	9	730
Alina Garbuzov United States	7	174 0.2×	192 0.4×	136 0.3×	166 0.5×	23 0.2×	7	593
Stephanie Y. Vernooy United States	5	189 0.2×	1.0k 1.9×	80 0.2×	51 0.1×	26 0.2×	7	1.3k
Anthony M. Brumby Australia	16	251 0.3×	1.0k 1.9×	189 0.4×	39 0.1×	133 1.0×	19	1.5k
D A Withers United States	9	307 0.4×	627 1.2×	242 0.5×	82 0.2×	290 2.1×	9	1.1k

Countries citing papers authored by Marc Grenley

Since Specialization

Citations

This map shows the geographic impact of Marc Grenley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Grenley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Grenley more than expected).

Fields of papers citing papers by Marc Grenley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Grenley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Grenley. The network helps show where Marc Grenley may publish in the future.

Co-authorship network of co-authors of Marc Grenley

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Grenley. A scholar is included among the top collaborators of Marc Grenley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Grenley. Marc Grenley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Derry, Jonathan M.J., Jason P. Frazier, Marc Grenley, et al.. (2023). Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment. Clinical Cancer Research. 29(18). 3813–3825. 17 indexed citations

Rajasekaran, Karthik, Thomas J. Ow, Cherie‐Ann O. Nathan, et al.. (2023). Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.. Journal of Clinical Oncology. 41(16_suppl). 2579–2579. 2 indexed citations

Hatton, Beryl A., Marc Grenley, Sally Ditzler, et al.. (2022). Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies. Cancer Research. 82(12_Supplement). 620–620. 1 indexed citations

Houlton, Jeffrey, Daniel Clayburgh, Ryan Li, et al.. (2022). 569 A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients. Regular and Young Investigator Award Abstracts. A596–A596. 3 indexed citations

Hatton, Beryl A., Marc Grenley, James Garnsey, et al.. (2019). Abstract 4136: Direct intratumoral microdosing via the CIVO® platform reveals anti-tumor immune responses induced by the SUMO inhibitor TAK-981. Cancer Research. 79(13_Supplement). 4136–4136. 1 indexed citations

Klinghoffer, Richard A., Matthew J. Thompson, Darin Davidson, et al.. (2018). Multidrug analyses in cancer patients via intratumoral microdosing with CIVO: A microinjection technology for phase 0 drug investigation.. Journal of Clinical Oncology. 36(15_suppl). e23569–e23569.

Dey, Joyoti, Thomas L. Deckwerth, William Kerwin, et al.. (2017). Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Scientific Reports. 7(1). 72 indexed citations

Dey, Joyoti, William Kerwin, Marc Grenley, et al.. (2016). A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. PLoS ONE. 11(6). e0158617–e0158617. 6 indexed citations

Dey, Joyoti, Sally Ditzler, Matthew C. Biery, et al.. (2016). Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition. Cancer Research. 76(14_Supplement). 2835–2835. 2 indexed citations

10.

Jiang, Huaqi, et al.. (2010). EGFR/Ras/MAPK Signaling Mediates Adult Midgut Epithelial Homeostasis and Regeneration in Drosophila. Cell stem cell. 8(1). 84–95. 356 indexed citations

11.

Jiang, Huaqi, Parthive H. Patel, Alexander Kohlmaier, et al.. (2009). Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the Drosophila Midgut. Cell. 137(7). 1343–1355. 776 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact